Kane Biotech Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KNBIF research report →
Companykanebiotech.com
Kane Biotech Inc. , a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; animal and human wound care solutions under the DispersinB name; shampoos for dogs, cats, and horses under the Alosera name; and medical device coatings under the Aledex name.
- CEO
- Robert Huizinga
- IPO
- 2007
- Employees
- 20
- HQ
- Winnipeg, MB, CA
Price Chart
Valuation
- Market Cap
- $4.06M
- P/E
- -2.09
- P/S
- 14.88
- P/B
- -7.61
- EV/EBITDA
- -2.63
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -38.18%
- Op Margin
- -727.40%
- Net Margin
- -636.00%
- ROE
- 374.19%
- ROIC
- -192.17%
Growth & Income
- Revenue
- $427.52K · -79.45%
- Net Income
- $-2,719,021 · -144.59%
- EPS
- $-0.02 · 29.24%
- Op Income
- $-3,109,787.2
- FCF YoY
- 22.46%
Performance & Tape
- 52W High
- $0.05
- 52W Low
- $0.02
- 50D MA
- $0.02
- 200D MA
- $0.03
- Beta
- 0.25
- Avg Volume
- 14.22K
Get TickerSpark's AI analysis on KNBIF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our KNBIF Coverage
We haven't published any research on KNBIF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate KNBIF Report →